Biotechnology

Kira Pharmaceuticals Announces IND Approval from Chinese NMPA for Phase 2 Evaluation of KP104 in Paroxysmal Nocturnal Hemoglobinuria (PNH)

CAMBRIDGE, Mass. and SUZHOU, China, Oct. 17, 2022 /PRNewswire/ -- Kira Pharmaceuticals, a global biotechnology company pioneering transformational complement therapies to treat immune-mediated diseases, announced today that the Chinese National Medical Products Administration (NMPA) has cleared t...

2022-10-17 07:31 1632

Chinese NMPA Approves Pivotal Phase III Study of TLX591-CDx for Prostate Cancer Imaging

MELBOURNE, Australia, Oct. 17, 2022 /PRNewswire/ -- Telix Pharmaceuticals Limited (ASX: TLX, Telix, the Company) today announces that the Chinese National Medical Products Administration (NMPA) Center for Drug Evaluation (CDE) has approved an investigational new drug (IND) application to commence...

2022-10-17 07:25 1377

Angel Yeast Announces to Promote Food Security and Sustainable Agriculture on the World Food Day

YICHANG, China, Oct. 16, 2022 /PRNewswire/ -- Angel Yeast , (SH600298), the world's leading yeast manufacturer, has announced it aims to play a larger role in increasing people's access to nutritious food, and making food systems more inclusive and sustainable, as par...

2022-10-16 21:00 2834

China Matters' Feature: How is Dongguan changing manufacturing with 3D printing?

BEIJING, Oct. 14, 2022 /PRNewswire/ -- Dongguan has long been known as the "factory of the world." The city has produced one third of the world's accessories and daily goods, and one out of six phones in the world is made from here. But over the recent years, the city has been shifting to a mode...

2022-10-14 21:22 3038

Tianfu International Biocity: Build Global Bioindustry-city

CHENGDU, China, Oct. 14, 2022 /PRNewswire/ -- On Oct.10, Chengdu Tianfu Global International Biocity saw the signing of ten project agreements totalling nearly 9B CNY in value and covering modern biopharmaceuticals, innovative chemical drugs, sophisticated medical apparatuses and other important f...

2022-10-14 20:48 1201

WuXi Biologics Receives "Best CDMO Award of the Year"

SHANGHAI, Oct. 13, 2022  /PRNewswire/ -- WuXi Biologics ("WuXi Bio") (2269.HK), a leading global Contract Research, Development and Manufacturing Organization (CRDMO), announced that it has received the "Best CDMO Award of the Year" at the Asia-Pacific Biologics CMO Excellence Awards (APBCEA) 202...

2022-10-14 09:00 1499

Alterity Therapeutics Launches ATH434 Phase 2 Clinical Trial in Australia for the Treatment of Individuals with Multiple System Atrophy

Australia now open for study of rare, rapidly progressive Parkinsonian Disorder MELBOURNE, Australia and SAN FRANCISCO, Oct. 13, 2022 /PRNewswire/ -- Alterity Therapeutics (ASX: ATH, NASDAQ: ATHE) ("Alterity" or "the Company"), a biotechnology company dedicated to developing disease modifying t...

2022-10-13 22:25 1086

Neurophth Therapeutics Conducts Special Interview with Dr. Satoshi Kashii on World Sight Day

WUHAN, China and SAN DIEGO, Calif., Oct. 13, 2022 /PRNewswire/ -- October 13th is World Sight Day.Today, Neurophth Therapeutics, Inc. has a special interview with Dr.Satoshi Kashii, Professor of Visual Sciences and Ophthalmology, Aichi Shukutoku University, President of Asian Neuro-Ophthalmology ...

2022-10-13 20:30 1903

Menarini Silicon Biosystems's CELLSEARCH® CMMC and HER2-CTC Liquid Biopsy Tests obtain Reimbursement Codes with Preliminary Pricing Determination

These new codes are required to access Medicare/Medicaid insurance reimbursement for novel CELLSEARCH Circulating Multiple Myeloma Cell (CMMC) and HER2 Circulating Tumor Cell (CTC-HER2) assays, to monitor disease status in patients with life-threatening illnesses. HUNTINGDON VALLEY, Pa., Oct. 13...

2022-10-13 20:00 1197

Harbour BioMed Announces Upcoming Poster Presentations at the 37th Society for Immunotherapy of Cancer Annual Meeting

CAMBRIDGE, Mass., ROTTERDAM, Netherlands and SUZHOU, China, Oct. 13, 2022 /PRNewswire/ -- Harbour BioMed (the "Company", HKEX: 02142), a global biopharmaceutical company committed to the discovery, development, and commercialization of novel antibody therapeutics focusing on oncology and immunol...

2022-10-13 19:05 1137

Samsung Biologics obtains three global ISO certifications

* Receives accreditation for information security management system, information security in cloud services, and anti-bribery management systems * First global CDMO to be ISO 27001 and ISO 27017 certified * Earns Excellence Award for Integrated Management System from BSI for its performance ...

2022-10-13 19:00 1248

Jacobio Pharma to Collaborate with Merck on Clinical Trial of JAB-21822 in Combination with Cetuximab

BEIJING, SHANGHAI and BOSTON, Oct. 13, 2022 /PRNewswire/ -- Jacobio announced it has entered into a clinical trial collaboration agreement with Merck on clinical study of combination therapy between Jacobio's KRAS G12C inhibitor JAB-21822 and Merck's epidermal growth factor receptor (EGFR) inhibi...

2022-10-13 09:00 1582

China Matters' Feature: How is Dongguan's new "super microscope" helping scientists dive deeper?

BEIJING, Oct. 12, 2022 /PRNewswire/ -- The Spallation Neutron Source, or SNS, in Dongguan works by using neutron beams which are able to penetrate materials with ease and provide a clear view of the inside structure. Dongguan's SNS is essentially a super microscope which allow scientists to exa...

2022-10-12 23:46 1442

Novavax Prototype COVID-19 Vaccine Data Support Homologous and Heterologous Boosting and Suggest Benefit Against Variants

* Homologous boosting with the prototype Novavax COVID-19 vaccine induced robust antibody titers for Omicron BA.1, BA.2, and BA.5 * Study 307 (Lot Consistency) achieved its primary endpoint, showing that three vaccine lots induced a comparable immune response thereby demonstrating the consist...

2022-10-12 21:35 1949

WuXi Biologics and Toregem BioPharma Sign MOU for Development of Anti-USAG-1 Antibody

SHANGHAI, Oct. 11, 2022 /PRNewswire/ -- WuXi Biologics ("WuXi Bio") (2269.HK), a leading global Contract Research, Development and Manufacturing Organization (CRDMO), and Toregem BioPharma, a biotech startup company fromKyoto University, today announced that they have signed a Memorandum of Under...

2022-10-12 09:00 1767

CSafe and BioLife Solutions, Inc. announce partnership to expand supply chain solutions for the cell and gene therapy market

CSafe joins BioLife's global partner network of cold chain solution providers using the evo® cold chain management platform MONROE, Ohio and BOTHELL, Wash., Oct. 11, 2022 /PRNewswire/ -- CSafe, one of the largest active and passive temperature-controlled shipping solutions providers for pharmace...

2022-10-11 22:10 2397

Great Bay Bio Announces Official Launch of Site-Specific Integration Platform for Cell Line Development, AlfaCell®

HONG KONG, Oct. 11, 2022 /PRNewswire/ -- Great Bay Bio (hereinafter referred to as "GBB") today announces the official launch of its self-developed AI-enabled site-specific integration platform for cell line development (CLD), AlfaCell®. AlfaCell® platform has pioneered to integrate GBB's proprie...

2022-10-11 20:40 1224

HanAll's Licensed Partner in China Enters Sublicense Agreement with CSPC to Further Accelerate Development of Batoclimab

* Harbour BioMed, HanAll's licensed partner in China, signed a sublicense agreement with CSPC NBP Pharmaceutical for batoclimab, an FcRn compound originally discovered and developed by HanAll Biopharma * Batoclimab is one of the most advanced FcRn inhibitors being developed in Greater China, ...

2022-10-11 19:00 1069

Samsung Biologics unlocks additional capacity for production at its newest Plant 4

* Plant 4 commences GMP operations within just 23 months since groundbreaking, as planned * Partial operations add fresh biomanufacturing capacity of 60,000 liters * Plant 4's total capacity of 240,000 liters to be ready early next year INCHEON,South Korea, Oct. 11, 2022 /PRNewswire/ -- Sams...

2022-10-11 19:00 1192

Pharming submits a Marketing Authorisation Application to the European Medicines Agency for Leniolisib

Application is based on randomized, controlled and long-term extension data for leniolisib as a treatment for APDS, a rare primary immunodeficiency  This submission follows the grant of accelerated assessment allowing an expedited review for leniolisib from a standard 210 days to 150 days LEIDEN...

2022-10-11 13:00 1442
1 ... 107108109110111112113 ... 279